Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price was up 4.3% on Tuesday . The company traded as high as $3.60 and last traded at $3.60. Approximately 600 shares traded hands during trading, an increase of 20% from the average daily volume of 500 shares. The stock had previously closed at $3.45.
Molecular Partners Stock Performance
The stock’s 50 day simple moving average is $3.71 and its two-hundred day simple moving average is $4.04.
Molecular Partners Company Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- What is the Australian Securities Exchange (ASX)
- The Drone Arms Race: From Battlefield to Balance Sheet
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why Wall Street Is Backing These 3 Comeback Stocks
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Intel’s Breakout Quarter: More Than a Beat, It’s a Declaration
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
